000181692 001__ 181692
000181692 005__ 20240229145654.0
000181692 0247_ $$2doi$$a10.1186/s13195-022-01063-y
000181692 0247_ $$2pmid$$apmid:36085081
000181692 0247_ $$2pmc$$apmc:PMC9461133
000181692 0247_ $$2altmetric$$aaltmetric:135819252
000181692 037__ $$aDKFZ-2022-02168
000181692 041__ $$aEnglish
000181692 082__ $$a610
000181692 1001_ $$0P:(DE-He78)b09508a4c4afe85c57dd131eefa689ea$$aTrares, Kira$$b0$$eFirst author$$udkfz
000181692 245__ $$aAssociation of the inflammation-related proteome with dementia development at older age: results from a large, prospective, population-based cohort study.
000181692 260__ $$aLondon$$bBioMed Central$$c2022
000181692 3367_ $$2DRIVER$$aarticle
000181692 3367_ $$2DataCite$$aOutput Types/Journal article
000181692 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1663225814_4970
000181692 3367_ $$2BibTeX$$aARTICLE
000181692 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000181692 3367_ $$00$$2EndNote$$aJournal Article
000181692 500__ $$a#EA:C070#LA:C070#
000181692 520__ $$aChronic inflammation is a central feature of several forms of dementia. However, few details on the associations of blood-based inflammation-related proteins with dementia incidence have been explored yet.The Olink Target 96 Inflammation panel was measured in baseline serum samples (collected 07/2000-06/2002) of 1782 older adults from a German, population-based cohort study in a case-cohort design. Logistic regression models were used to assess the associations of biomarkers with all-cause dementia, Alzheimer's disease, and vascular dementia incidence.During 17 years of follow-up, 504 participants were diagnosed with dementia, including 163 Alzheimer's disease and 195 vascular dementia cases. After correction for multiple testing, 58 out of 72 tested (80.6%) biomarkers were statistically significantly associated with all-cause dementia, 22 with Alzheimer's disease, and 33 with vascular dementia incidence. We identified four biomarker clusters, among which the strongest representatives, CX3CL1, EN-RAGE, LAP TGF-beta-1, and VEGF-A, were significantly associated with dementia endpoints independently from other inflammation-related proteins. CX3CL1 (odds ratio [95% confidence interval] per 1 standard deviation increase: 1.41 [1.24-1.60]) and EN-RAGE (1.41 [1.25-1.60]) were associated with all-cause dementia incidence, EN-RAGE (1.51 [1.25-1.83]) and LAP TGF-beta-1 (1.46 [1.21-1.76]) with Alzheimer's disease incidence, and VEGF-A (1.43 [1.20-1.70]) with vascular dementia incidence. All named associations were stronger among APOE ε4-negative subjects.With this large, population-based cohort study, we show for the first time that the majority of inflammation-related proteins measured in blood samples are associated with total dementia incidence. Future studies should concentrate not only on single biomarkers but also on the complex relationships in biomarker clusters.
000181692 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000181692 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000181692 650_7 $$2Other$$aAlzheimer’s disease
000181692 650_7 $$2Other$$aBiomarker
000181692 650_7 $$2Other$$aCohort study
000181692 650_7 $$2Other$$aDementia
000181692 650_7 $$2Other$$aInflammation
000181692 650_7 $$2Other$$aVascular dementia
000181692 650_7 $$2NLM Chemicals$$aProteome
000181692 650_7 $$2NLM Chemicals$$aTransforming Growth Factor beta1
000181692 650_7 $$2NLM Chemicals$$aVascular Endothelial Growth Factor A
000181692 650_2 $$2MeSH$$aAged
000181692 650_2 $$2MeSH$$aAlzheimer Disease: epidemiology
000181692 650_2 $$2MeSH$$aCohort Studies
000181692 650_2 $$2MeSH$$aDementia, Vascular: epidemiology
000181692 650_2 $$2MeSH$$aHumans
000181692 650_2 $$2MeSH$$aInflammation: epidemiology
000181692 650_2 $$2MeSH$$aProspective Studies
000181692 650_2 $$2MeSH$$aProteome
000181692 650_2 $$2MeSH$$aTransforming Growth Factor beta1
000181692 650_2 $$2MeSH$$aVascular Endothelial Growth Factor A
000181692 7001_ $$0P:(DE-He78)ac7aed57f26354e8a484b5d257f7bada$$aBhardwaj, Megha$$b1$$udkfz
000181692 7001_ $$aPerna, Laura$$b2
000181692 7001_ $$0P:(DE-He78)104fae0755c89365b7ae32238b3f1f52$$aStocker, Hannah$$b3$$udkfz
000181692 7001_ $$aPetrera, Agnese$$b4
000181692 7001_ $$aHauck, Stefanie M$$b5
000181692 7001_ $$aBeyreuther, Konrad$$b6
000181692 7001_ $$0P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aBrenner, Hermann$$b7$$udkfz
000181692 7001_ $$0P:(DE-He78)c67a12496b8aac150c0eef888d808d46$$aSchöttker, Ben$$b8$$eLast author$$udkfz
000181692 773__ $$0PERI:(DE-600)2506521-X$$a10.1186/s13195-022-01063-y$$gVol. 14, no. 1, p. 128$$n1$$p128$$tAlzheimer's research & therapy$$v14$$x1758-9193$$y2022
000181692 909CO $$ooai:inrepo02.dkfz.de:181692$$pVDB
000181692 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)b09508a4c4afe85c57dd131eefa689ea$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000181692 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)ac7aed57f26354e8a484b5d257f7bada$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000181692 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)104fae0755c89365b7ae32238b3f1f52$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000181692 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000181692 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)c67a12496b8aac150c0eef888d808d46$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000181692 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000181692 9141_ $$y2022
000181692 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2021-05-04
000181692 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-05-04
000181692 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-05-04
000181692 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2021-05-04
000181692 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2021-05-04
000181692 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bALZHEIMERS RES THER : 2021$$d2022-11-08
000181692 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2022-11-08
000181692 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-08
000181692 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2021-02-14T16:18:57Z
000181692 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2021-02-14T16:18:57Z
000181692 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Peer review$$d2021-02-14T16:18:57Z
000181692 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2022-11-08
000181692 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2022-11-08
000181692 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-08
000181692 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-08
000181692 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2022-11-08
000181692 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bALZHEIMERS RES THER : 2021$$d2022-11-08
000181692 9202_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x0
000181692 9201_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x0
000181692 9200_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x0
000181692 980__ $$ajournal
000181692 980__ $$aVDB
000181692 980__ $$aI:(DE-He78)C070-20160331
000181692 980__ $$aUNRESTRICTED